Structure activity relationships of chrysoeriol and analogs as dual c‑Met and VEGFR2 tyrosine kinase inhibitors

Lai,Shuang; Chen,Jun‑Ning; Huang,Han‑Wei; Zhang,Xiang‑Yu; Jiang,Hai‑Lun; Li,Wei; Wang,Peng‑Liang; Wang,Jian; Liu,Fu‑Nan

doi:10.3892/or.2018.6542

Structure activity relationships of chrysoeriol and analogs as dual c‑Met and VEGFR2 tyrosine kinase inhibitors

Authors:
- Shuang Lai
- Jun‑Ning Chen
- Han‑Wei Huang
- Xiang‑Yu Zhang
- Hai‑Lun Jiang
- Wei Li
- Peng‑Liang Wang
- Jian Wang
- Fu‑Nan Liu
View Affiliations

Affiliations: Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Key Laboratory of Structure‑Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China, Department of Surgical Oncology and General Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Pharmaceutical Engineering, Shenyang University of Chemical Technology, Shenyang, Liaoning 110042, P.R. China
Published online on: July 2, 2018 https://doi.org/10.3892/or.2018.6542
Pages: 1650-1656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor receptor 2 (VEGFR2) and c‑Met are tyrosine kinases, which are involved in the tumorigenesis of various types of cancer. Previous studies have demonstrated that the elevated activation of c‑Met is associated with the drug resistance of VEGFR2 inhibitors. Therefore, dual c‑Met and VEGFR2 kinase inhibitors are expected to overcome VEGFR2 inhibitor resistance and subsequently lead to a superior therapeutic outcome to regular VEGFR2 inhibitors. In the present study, it was found that chrysoeriol, which can be extracted from several natural plants, was a potential dual c‑Met and VEGFR2 kinase inhibitor. The results of docking experiments revealed that chrysoeriol was able to efficiently bind in the active site cavity of c‑Met and VEGFR2. The results of enzymatic assays showed relatively high binding affinities of chrysoeriol to c‑Met (Kd=12 µM) and VEGFR2 (Kd=11 µM). The structure activity relationships (SARs) of chrysoeriol and its analogs were investigated using pharmacological and molecular docking experiments. To the best of our best knowledge, the present study is the first to report a natural product with both c‑Met and VEGFR2 inhibitory profiles, and provides insights into future dual c‑Met and VEGFR2 kinase inhibitor development.

View Figures

View References

1	Vaupel P: The role of hypoxia-induced factors in tumor progression. The Oncologist. Suppl 5:S10–S17. 2004. View Article : Google Scholar
2	Carmeliet P: Angiogenesis in health and disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
3	Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, et al: Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69:8009–8016. 2009. View Article : Google Scholar : PubMed/NCBI
4	Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, et al: Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors. Bioorg Med Chem. 21:7686–7698. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zhan Z, Ai J, Liu Q, Ji Y, Chen T, Xu Y, Geng M and Duan W: Discovery of anilinopyrimidines as dual inhibitors of c-met and VEGFR-2: Synthesis, SAR, and cellular activity. ACS Med Chem Lett. 5:673–678. 2014. View Article : Google Scholar : PubMed/NCBI
6	Mizuno S and Nakamura T: Hepatocyte growth factor: A regenerative drug for acute hepatitis and liver cirrhosis. Regen Med. 2:161–170. 2007. View Article : Google Scholar : PubMed/NCBI
7	Molnarfi N, Benkhoucha M, Funakoshi H, Nakamura T and Lalive PH: Hepatocyte growth factor: A regulator of inflammation and autoimmunity. Autoimmun Rev. 14:293–303. 2015. View Article : Google Scholar : PubMed/NCBI
8	Yap TA and de Bono JS: Targeting the HGF/c-Met axis: State of play. Mol Cancer Ther. 9:1077–1079. 2010. View Article : Google Scholar : PubMed/NCBI
9	Yang X, Zhang Y, Yang Y, Lim S, Cao Z, Rak J and Cao Y: Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci USA. 110:13932–13937. 2013. View Article : Google Scholar : PubMed/NCBI
10	Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J and Ouyang L: Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. Eur J Med Chem. 108:495–504. 2016. View Article : Google Scholar : PubMed/NCBI
11	De Falco S, Gigante B and Persico MG: Structure and function of placental growth factor. Trends Cardiovasc Med. 12:241–246. 2002. View Article : Google Scholar : PubMed/NCBI
12	Nishimoto RN: OFIRMEV: An old drug becomes new again. Anesth Prog. 61:99–102. 2014. View Article : Google Scholar : PubMed/NCBI
13	Chen H, Wu J, Gao Y, Chen H and Zhou J: Scaffold repurposing of old drugs towards new cancer drug discovery. Curr Top Med Chem. 16:2107–2114. 2016. View Article : Google Scholar : PubMed/NCBI
14	Cai ZW, Wei D, Schroeder GM, Cornelius LA, Kim K, Chen XT, Schmidt RJ, Williams DK, Tokarski JS, An Y, et al: Discovery of orally active pyrrolopyridine- and aminopyridine-based met kinase inhibitors. Bioorg Med Chem Lett. 18:3224–3229. 2008. View Article : Google Scholar : PubMed/NCBI
15	Cui JJ, McTigue M, Nambu M, Tran-Dubé M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P, et al: Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. J Med Chem. 55:8091–8109. 2012. View Article : Google Scholar : PubMed/NCBI
16	Oguro Y, Miyamoto N, Okada K, Takagi T, Iwata H, Awazu Y, Miki H, Hori A, Kamiyama K and Imamura S: Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: Novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg Med Chem. 18:7260–7273. 2010. View Article : Google Scholar : PubMed/NCBI
17	Fabian MA, Biggs WH III, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 23:329–336. 2005. View Article : Google Scholar : PubMed/NCBI
18	Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 26:127–132. 2008. View Article : Google Scholar : PubMed/NCBI